Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results

M. R A Khairi, Roy D Altman, G. P. DeRosa, J. Zimmermann, R. K. Schenk, C. C. Johnston

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Subjects (109) with symptomatic Paget's disease of bone were treated with 5, 10, or 20 mg of sodium etidronate (EHDP)/kg body weight/day for 6 to 24 mth. Significant decreases in serum alkaline phosphatase and urinary hydroxyproline were noted after 6 mth of therapy; no significant further improvement resulted after prolonged therapy. Some patients maintained biochemical remission after withdrawal of EHDP but others showed a relapse, related primarily to the pretreatment severity. Clinical improvement was noted in 61% of the patients. Similar findings were seen after a second course of EHDP. No side-effects were noted in patients treated with 5 mg of EHDP/kg body weight/day. In patients treated with 10 or 20 mg of EHDP/kg body weight/day, severe diarrhea, bone pain, and nontraumatic fractures were noted in 3, 13, and 12 patients respectively. Quantitative histomorphometry showed mineralization delay in patients receiving 10 or 20 mg of EHDP/kg body weight/day but not in those receiving 5 mg/kg body weight/day. Five milligrams of EHDP/kg body weight/day was effective and appears to be safer than the higher doses.

Original languageEnglish (US)
Pages (from-to)656-663
Number of pages8
JournalAnnals of Internal Medicine
Volume87
Issue number6
StatePublished - 1977
Externally publishedYes

Fingerprint

Etidronic Acid
Osteitis Deformans
Body Weight
Therapeutics
Hydroxyproline
Alkaline Phosphatase
Diarrhea
Bone and Bones
Recurrence
Pain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Khairi, M. R. A., Altman, R. D., DeRosa, G. P., Zimmermann, J., Schenk, R. K., & Johnston, C. C. (1977). Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results. Annals of Internal Medicine, 87(6), 656-663.

Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results. / Khairi, M. R A; Altman, Roy D; DeRosa, G. P.; Zimmermann, J.; Schenk, R. K.; Johnston, C. C.

In: Annals of Internal Medicine, Vol. 87, No. 6, 1977, p. 656-663.

Research output: Contribution to journalArticle

Khairi, MRA, Altman, RD, DeRosa, GP, Zimmermann, J, Schenk, RK & Johnston, CC 1977, 'Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results', Annals of Internal Medicine, vol. 87, no. 6, pp. 656-663.
Khairi MRA, Altman RD, DeRosa GP, Zimmermann J, Schenk RK, Johnston CC. Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results. Annals of Internal Medicine. 1977;87(6):656-663.
Khairi, M. R A ; Altman, Roy D ; DeRosa, G. P. ; Zimmermann, J. ; Schenk, R. K. ; Johnston, C. C. / Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results. In: Annals of Internal Medicine. 1977 ; Vol. 87, No. 6. pp. 656-663.
@article{43f222976bcf426bb77fe9d1d6cb121a,
title = "Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results",
abstract = "Subjects (109) with symptomatic Paget's disease of bone were treated with 5, 10, or 20 mg of sodium etidronate (EHDP)/kg body weight/day for 6 to 24 mth. Significant decreases in serum alkaline phosphatase and urinary hydroxyproline were noted after 6 mth of therapy; no significant further improvement resulted after prolonged therapy. Some patients maintained biochemical remission after withdrawal of EHDP but others showed a relapse, related primarily to the pretreatment severity. Clinical improvement was noted in 61{\%} of the patients. Similar findings were seen after a second course of EHDP. No side-effects were noted in patients treated with 5 mg of EHDP/kg body weight/day. In patients treated with 10 or 20 mg of EHDP/kg body weight/day, severe diarrhea, bone pain, and nontraumatic fractures were noted in 3, 13, and 12 patients respectively. Quantitative histomorphometry showed mineralization delay in patients receiving 10 or 20 mg of EHDP/kg body weight/day but not in those receiving 5 mg/kg body weight/day. Five milligrams of EHDP/kg body weight/day was effective and appears to be safer than the higher doses.",
author = "Khairi, {M. R A} and Altman, {Roy D} and DeRosa, {G. P.} and J. Zimmermann and Schenk, {R. K.} and Johnston, {C. C.}",
year = "1977",
language = "English (US)",
volume = "87",
pages = "656--663",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "6",

}

TY - JOUR

T1 - Sodium etidronate in the treatment of Paget's disease of bone. A study of long-term results

AU - Khairi, M. R A

AU - Altman, Roy D

AU - DeRosa, G. P.

AU - Zimmermann, J.

AU - Schenk, R. K.

AU - Johnston, C. C.

PY - 1977

Y1 - 1977

N2 - Subjects (109) with symptomatic Paget's disease of bone were treated with 5, 10, or 20 mg of sodium etidronate (EHDP)/kg body weight/day for 6 to 24 mth. Significant decreases in serum alkaline phosphatase and urinary hydroxyproline were noted after 6 mth of therapy; no significant further improvement resulted after prolonged therapy. Some patients maintained biochemical remission after withdrawal of EHDP but others showed a relapse, related primarily to the pretreatment severity. Clinical improvement was noted in 61% of the patients. Similar findings were seen after a second course of EHDP. No side-effects were noted in patients treated with 5 mg of EHDP/kg body weight/day. In patients treated with 10 or 20 mg of EHDP/kg body weight/day, severe diarrhea, bone pain, and nontraumatic fractures were noted in 3, 13, and 12 patients respectively. Quantitative histomorphometry showed mineralization delay in patients receiving 10 or 20 mg of EHDP/kg body weight/day but not in those receiving 5 mg/kg body weight/day. Five milligrams of EHDP/kg body weight/day was effective and appears to be safer than the higher doses.

AB - Subjects (109) with symptomatic Paget's disease of bone were treated with 5, 10, or 20 mg of sodium etidronate (EHDP)/kg body weight/day for 6 to 24 mth. Significant decreases in serum alkaline phosphatase and urinary hydroxyproline were noted after 6 mth of therapy; no significant further improvement resulted after prolonged therapy. Some patients maintained biochemical remission after withdrawal of EHDP but others showed a relapse, related primarily to the pretreatment severity. Clinical improvement was noted in 61% of the patients. Similar findings were seen after a second course of EHDP. No side-effects were noted in patients treated with 5 mg of EHDP/kg body weight/day. In patients treated with 10 or 20 mg of EHDP/kg body weight/day, severe diarrhea, bone pain, and nontraumatic fractures were noted in 3, 13, and 12 patients respectively. Quantitative histomorphometry showed mineralization delay in patients receiving 10 or 20 mg of EHDP/kg body weight/day but not in those receiving 5 mg/kg body weight/day. Five milligrams of EHDP/kg body weight/day was effective and appears to be safer than the higher doses.

UR - http://www.scopus.com/inward/record.url?scp=0017587282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017587282&partnerID=8YFLogxK

M3 - Article

VL - 87

SP - 656

EP - 663

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 6

ER -